Pulse ·
17,000 women later: what the NSW pharmacy UTI trial showed
A NSW pharmacy-led trial for uncomplicated urinary tract infections treated more than 17,000 women in its first year under a strict state-approved protocol covering women aged 18–65 with classic UTI symptoms only. Nearly 80% reported complete symptom resolution at one week; around 7% were referred to GPs or emergency departments.
The results have renewed debate about pharmacist scope of practice. For classic uncomplicated UTIs in otherwise healthy women, the available evidence supports pharmacist-led management under protocol. For atypical presentations — fever, back pain, recurrent infections — a GP or urgent care visit remains the appropriate first step.
In the year after NSW launched its pharmacist-led urinary tract infection service, more than 17,000 women walked into a pharmacy instead of waiting for a GP appointment. Most had uncomplicated UTIs — classic symptoms in otherwise healthy women aged 18 to 65. Most left with an antibiotic script. At one week follow-up, nearly 80% reported complete symptom resolution.
The debate this result has reignited is not really about those 17,000 women. It is about what their experience means for the boundary between pharmacy and general practice — and whether those boundaries, as currently drawn, are serving patients or protecting professions.
What the trial actually did
The NSW pharmacy UTI service operates under a strict, state-approved clinical protocol. Eligible patients are women aged 18 to 65 presenting with classic uncomplicated UTI symptoms — dysuria, frequency, urgency — without features suggesting upper tract involvement: no fever, no flank pain, no systemic illness. The protocol specifies which antibiotic to prescribe, mandates a clinical assessment before dispensing, and requires referral to a GP or emergency department if the presentation falls outside eligibility criteria.
In the first year, around 7% of presentations were referred on. No significant safety signals were identified. Prescribing aligned with best-practice guidelines. The model was designed to address a documented access problem: one in five women aged 18 to 34 currently waits more than three weeks for a GP appointment. An untreated lower tract infection during a three-week wait is miserable at best and dangerous at worst — upper tract spread can develop from an untreated lower tract infection, and pyelonephritis carries real morbidity.
Both-and
The case against pharmacist-led UTI management — and it is a case worth taking seriously, not dismissing — centres on diagnostic uncertainty. UTI symptoms are not pathognomonic. Dysuria and frequency can signal chlamydia, candidal vaginitis, interstitial cystitis, or early pelvic inflammatory disease. A GP assessment includes clinical context that a pharmacy assessment does not: sexual history, prior UTI pattern, concurrent symptoms, examination findings where relevant.
Critics have argued — with some justification — that a high symptom-resolution rate does not distinguish between pharmacist-led management being effective versus patients who would have resolved regardless (many uncomplicated UTIs are self-limiting) or patients whose symptoms had a different cause that happened to co-resolve or remain undiagnosed.
These are legitimate methodological questions. They do not disappear because 17,000 women reported positive outcomes.
What the defenders of the trial respond — and this is also worth weighing — is that symptom-based diagnosis of uncomplicated UTI is already standard practice in general practice. RACGP and eTG guidelines both support empirical treatment without universal pathology testing in classic presentations in otherwise healthy women. Holding pharmacist-led management to a higher diagnostic standard than GP-led management is not a scientific position. It is a credentialling one.
There is also the structural reality. Australia has a documented shortage of accessible GP appointments. Scope-of-practice debates conducted in the abstract tend to resolve one way when a clinic has a two-week wait and a patient has symptoms that make sitting down painful.
My two cents
The scope-of-practice debate in Australian healthcare is often framed as a binary: pharmacists doing more versus GPs doing everything. That framing helps nobody. The useful question is not whether pharmacists should replace GPs in UTI management, but which specific presentations are safe and appropriate for pharmacist-led care under protocol — and what the referral pathway looks like when the presentation is atypical.
The NSW trial answers that question for the straightforward end of the spectrum. The answer, on the available evidence, is that pharmacist-led management of classic uncomplicated UTIs in healthy women aged 18 to 65, under strict protocol, is safe and achieves clinically reasonable outcomes for most of the eligible population. That does not mean every pharmacy interaction carries the same diagnostic rigour. It means this specific protocol, in this specific population, with this specific referral rate, produced outcomes that are defensible.
The antimicrobial stewardship question is important and genuinely unresolved. The trial reports prescribing aligned with guidelines; whether pharmacist-led management at scale contributes to resistance pressures over time requires longer follow-up than a one-year pilot can provide. This is a legitimate watch item, not a reason to dismiss the trial’s findings.
For patients: if you have classic UTI symptoms — frequency, burning, urgency, no fever or back pain — and cannot get a GP appointment within 48 hours, the NSW pharmacy service represents an evidence-informed option for this specific presentation. If your symptoms include fever, back pain, nausea, recurrent infections, or anything that doesn’t fit the simple picture, a GP or urgent care visit remains the right first step. The protocol was designed with exactly these distinctions in mind.
Verdict: maybe — the trial results are encouraging for the specific eligible population, but scope-of-practice and stewardship questions remain genuinely open.